Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors by Jun J Mao et al.
RESEARCH ARTICLE Open Access
Association of functional polymorphisms in
CYP19A1 with aromatase inhibitor associated
arthralgia in breast cancer survivors
Jun J Mao1,2*†, H Irene Su3†, Rui Feng4, Michelle L Donelson4, Richard Aplenc5, Timothy R Rebbeck2,4,
Frank Stanczyk6, Angela DeMichele2,4,6
Abstract
Introduction: Aromatase inhibitor-associated arthralgia (AIAA) is a common and often debilitating symptom in
breast cancer survivors. Since joint symptoms have been related to estrogen deprivation through the menopausal
transition, we hypothesized that genetic polymorphisms in CYP19A1, the final enzyme in estrogen synthesis, may
be associated with the occurrence of AIAA.
Methods: We performed a cross-sectional study of postmenopausal women with stage 0 to III breast cancer
receiving adjuvant aromatase inhibitor (AI) therapy. Patient-reported AIAA was the primary outcome. DNA was
genotyped for candidate CYP19A1 polymorphisms. Serum estrogen levels were evaluated by radioimmunoassay.
Multivariate analyses were performed to examine associations between AIAA and genetic variants controlling for
possible confounders.
Results: Among 390 Caucasian participants, 50.8% reported AIAA. Women carrying at least one 8-repeat allele had
lower odds of AIAA (adjusted odds ratio (AOR) 0.41, 95% confidence interval (CI) 0.21 to 0.79, P = 0.008) after
adjusting for demographic and clinical covariates. Estradiol and estrone were detectable in 47% and 86% of
subjects on AIs, respectively. Although these post-AI levels were associated with multiple genotypes, they were not
associated with AIAA. In multivariate analyses, women with more recent transition into menopause (less than five
years) were significantly more likely to report AIAA than those greater than ten years post-menopause (AOR 3.31,
95% CI 1.72 to 6.39, P < 0.001).
Conclusions: Functional polymorphism in CYP19A1 and time since menopause are associated with patient-
reported AIAA, supporting the hypothesis that the host hormonal environment contributes to the pathophysiology
of AAIA. Prospective investigation is needed to further delineate relationships between host genetics, changing
estrogen levels and AIAA.
Introduction
Joint pain, or arthralgia, has emerged as a major symp-
tom in breast cancer survivors on aromatase inhibitors
(AIs) for adjuvant hormonal therapy [1,2]. In clinical
settings outside of therapeutic trials, close to half of
patients on AIs attribute arthralgia to this class of medi-
cation [3,4]. AI-associated arthralgia (AIAA) results not
only in decreased function [5], but also in premature
discontinuation and sub-optimal adherence [6]. Thus,
this symptom has the potential to impair both quality of
life and drug effectiveness.
Although the pathophysiology of AIAA remains
unclear, estrogen suppression is hypothesized to play an
important role, since AIs block the final step in estradiol
and estrone synthesis [7]. Natural menopause has been
associated with increased joint aches and stiffness;
symptoms are most prominent during the late meno-
pausal transition when marked falls in circulating estro-
gen levels occur [8]. Among breast cancer survivors,
* Correspondence: maoj@uphs.upenn.edu
† Contributed equally
1Department of Family Medicine and Community Health, University of
Pennsylvania School of Medicine, 3400 Spruce Street/2 Gates, Philadelphia, PA
19104, USA
Full list of author information is available at the end of the article
Mao et al. Breast Cancer Research 2011, 13:R8
http://breast-cancer-research.com/content/13/1/R8
© 2011 Mao et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
clinical risk factors associated with AIAA include
shorter time since menopause [3] and chemotherapy
exposure [4], which further diminishes residual ovarian
estrogen production. Thus, estrogen suppression, the
main effect of AI exposure, appears linked to arthralgia.
Aromatase enzyme, encoded by CYP19A1 and inhib-
ited by AIs, contains common genetic variants that have
been associated with circulating estrogen levels in post-
menopausal women [9-12]. In particular, intron 4 con-
tains a tetranucleotide repeat polymorphism (TTTA)n =
7-13 associated with estrogen levels. Postmenopausal
women who carry at least one 7-repeat allele (TTTA7)
have been found to have lower circulating estrone and
estradiol levels; those who carry at least one 8 -repeat
allele (TTTA8) have been noted to have higher estrone
and estradiol levels, compared to those with all other
repeat lengths.
Since polymorphisms in CYP19A1 impact estrogen
levels, we hypothesized that the presence of functional
polymorphisms in this gene would be associated with
AIAA among postmenopausal breast cancer survivors
on AI therapy. To test this hypothesis, we performed a
cross-sectional study of postmenopausal women taking
AIs to evaluate whether these polymorphisms were asso-
ciated with patient-reported occurrence of AIAA. Addi-
tionally, we tested the feasibility of measuring estradiol
and estrone levels in postmenopausal women on AIs
and explored their association with candidate genotypes
and AAIA.
Materials and methods
Study design and patient population
The Wellness After Breast Cancer (WABC) Study is a
cross-sectional study conducted between March 2008 and
July 2009 at the Rowan Breast Cancer Center of the
Abramson Cancer Center of the University of Pennsylva-
nia (Philadelphia, PA, USA). Eligibility criteria included
postmenopausal status (≥12 months of amenorrhea), his-
tory of histologically-confirmed hormone receptor-
positive breast cancer, AJCC stages 0 to III, and exposure
to a third-generation aromatase inhibitor (anastrozole,
letrozole, or exemestane). Additional eligibility criteria
included completion of all chemotherapy and/or radio-
therapy at least one month prior to enrollment, approval
of the patient’s primary oncologist, and ability to provide
informed consent. Research assistants screened medical
records and approached potential patients for enrollment
at their regular follow-up appointments. After informed
consent was obtained, each participant completed a self-
administered survey. Peripheral blood was collected;
whole blood and serum samples were banked at -80°C
for genetic and biomarker analysis, respectively. The
study was approved by the Institutional Review Board of
the University of Pennsylvania.
Outcome measurement
We first asked whether participants experienced ongoing
joint pain, or arthralgia. Because arthralgia in a post-
menopausal female population can be multi-factorial, we
then specifically asked participants to attribute their cur-
rent arthralgia to several factors included aging, AIs, and
other medical conditions and medications. As in our
prior work, patients who reported AI as a current cause
of arthralgia were defined as having AAIA [3]. We also
asked those who stopped AIs for discontinuation rea-
sons. Because AIAA is an important cause of premature
discontinuation of therapy [13], those who reported
stopping AIs because of joint pain or musculoskeletal
problems were also classified as having AIAA.
Multiple covariates were ascertained. Patients
self-reported demographic variables included age, race/
ethnicity, education status, height, weight, date of last
menstrual period (LMP) and reasons for menopause
(natural, surgery, chemotherapy, hormonal therapy, and
other). Clinical variables such as cancer stage, prior che-
motherapy, current aromatase inhibitor use, and time
since AI start were obtained via chart abstraction and
verified by an oncologist (AD) for quality control.
Polymorphism selection and genotyping
Detailed literature and National Center for Biotechnol-
ogy Information single nucleotide polymorphism data-
base searches were performed to identify variants in
CYP19A1 that (1) had a functional impact on gene
expression, (2) were associated with either estrogen
levels, arthralgia or estrogen withdrawal symptoms in
the literature, and (3) had minor allele frequencies
of >10%. Five variants in CYP19A1 met these criteria.
Variants in CYP19A1 (IVS1 G/A (rs749292), IVS2
C/A (rs727479), 3’UTR T/C (rs10046), IVS4 -/TCT
(rs11575899), TTTAn (rs60271534)) are associated with
estrogen levels [9,10,14] and/or hot flashes, another
symptom related to estrogen withdrawal [12].
Genomic DNA was extracted from stored blood sam-
ples using the Qiagen QiaAmp 96 DNA Blood Kit
(Valencia, CA, USA). Laboratory personnel were blinded
to all clinical and outcome data. Genotyping for
CYP19A1 TTTAn was performed using site-specific pri-
mers for PCR amplification according to Woods et al.
[12] and Kelberman et al. [15] with modifications to
PCR conditions followed by direct sequencing. For all
other SNPs, genotyping was performed using Applied
Biosystems’ SNPlex platform (Foster City, CA, USA).
Estrone and estradiol levels
Serum samples were assayed for estradiol and estrone
levels. Samples underwent organic solvent extraction
followed by Celite column partition chromatography,
followed by radioimmunoassay to quantify estrone and
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estradiol, the primary circulating hormones in postme-
nopausal women. Assays were performed in duplicate,
and means of duplicates were analyzed. The intra- and
inter-assay coefficients of variation were <7% and 12%,
respectively. The lower limits of detection for estradiol
and estrone were 1.5 pg/mL and 1.7 pg/mL, respectively.
Values below detection thresholds were given half of the
threshold value in analyses.
Statistical analysis
Data analysis was performed using STATA 10.0 for
Windows (STATA Corporation, College Station, TX,
USA). Because genetic heterogeneity, or population stra-
tification, could lead to either spurious association or
reduced power, we carried out population-specific analy-
sis and report the results restricted to Caucasian sub-
jects since the number of subjects in other ethnic
groups was relatively small. For quality control, Hardy-
Weinberg Equilibrium was assessed for each polymorph-
ism using the Pearson chi square test.
First, we examined the association between AIAA and
polymorphisms using the c2 test. Additive, dominant
and recessive models were tested separately. The asso-
ciation between AIAA and clinical and demographic
variables was tested using the c2 test or Student’s t-test,
as appropriate. Covariates with P-values < 0.2 in bivari-
able analyses were carried forward to the multivariable
model. Because estrogen levels were not normally dis-
tributed (even with logarithmic transformation), the
Kruskal-Wallis test was used to compare estrogen levels
by genotype and AIAA status.
For those genotypes that were found to be significant
in the first step, we further determined the gene-
outcome association using multivariate logistic regression
models, adjusting for covariates including education,
length of time since menopause, reasons for menopause,
time since start of AI therapy, and chemotherapy regi-
men. Bonferroni correction was applied because five
polymorphisms were tested, and the level of significance
was adjusted to P < 0.01.
Results
Participant characteristics
Of 643 consecutive patients screened, 538 (83.7%)
agreed to participate. Among 105 who declined (16.3%),
the main reasons were: lack of time to complete survey
(n = 26, 4%); did not want to participate in research
(n = 43; 6.7%); and did not want to have an extra blood
draw (n = 36; 5.6%). Additionally, one subject withdrew
consent and nine subjects (1.4%) were further disquali-
fied because they did not meet eligibility criteria upon
further review. Of 528 subjects who returned data
(82.1%), 501 (77.9%) had both an evaluable survey and
a blood sample. Twenty-five subjects were further
excluded after chart review revealed metastatic disease
(3.9%), resulting in the final sample of 476. This popula-
tion reflected a 74% response rate among all initially
approached subjects and a 78% response rate among
those eligible.
For this study, we restricted analysis to the 390 Caucasian
subjects (81.9%) out of the entire sample. Among these
subjects (Table 1), mean age was 61.6 (standard devia-
tion (SD) 9.9); 206 subjects (56%) had gone through
natural menopause. Seventy-six subjects (19.0%) were
within five years of menopause, while more than half
(53%) reported being greater than 10 years from meno-
pause. Overall, 355 (91%) were currently taking an AI at
the time of enrollment, while 9% had discontinued AI
therapy by the time of the survey. Among those cur-
rently taking an AI, the majority (67.9%) was taking
anastrozole. Of the 35 subjects who had discontinued
Table 1 Demographic characteristics of participants
N %
Total (N, %) 390 81.9
Age, years (Mean, SD) 61.6 9.88
Educational Level (N, %)
High school or less 69 17.7
College or more 321 82.3
Reasons for menopause (N, %)
Natural 206 55.7
Induced 164 44.3
Years since LMP (N, %)
<5 76 19.8
5 to 10 104 27.1
>10 204 53.1
Body mass index, kg/m2 (Mean, SD) 26.7 5.6
Stage (N, %)





Chemotherapy, but no Taxane 97 24.9
Chemotherapy included Taxane 150 38.5
Currently on AIs 355 91
Aromatase inhibitors1
Letrozole (Femara) 71 20.0
Anastrozole (Arimidex) 241 67.9
Exemestane (Aromasin) 43 12.1
Years since start of AI1
<1 114 31.9
1 to 3 111 31.1
>3 132 37.0
Abbreviations: AIs, aromatase inhibitors; LMP, last menstrual period; SD,
standard deviation.
1Among those who are currently on AIs.
Not all cells add up due to missing variables.
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AI treatment, median time since discontinuation (IQR)
was 10.2 months (31).
Patient-reported AI-associated arthralgia
Among the participants, 198 (50.8%) reported joint
symptoms attributable to AI or cited arthralgia as reason
for their discontinuation of AIs, and were therefore clas-
sified as having AIAA. Risk of AIAA was non-statisti-
cally higher among those who stopped AIs than among
those who were currently on AIs (62.9% vs. 49.6%, P =
0.13). Shorter time since menopause (P < 0.001), expo-
sure to chemotherapy including taxane (P = 0.006), and
one to three years since the start of AI exposure (P =
0.02) appeared to be associated with greater report of
AAIA in univariate analysis (Table 2). Those with AIAA
were significantly younger than those without AIAA
(59 vs. 65, P < 0.001) but had similar body mass index
(BMI) (27.3 vs. 27.6, P = 0.85).
CYP19A1 polymorphisms
All genotyping failure rates were <1.8%. Genotype distri-
butions were in Hardy-Weinberg equilibrium and were
consistent with reported reference SNP frequencies.
Univariate associations between CYP19A1 (aromatase)
polymorphisms and study outcomes demonstrated that
subjects with at least one (TTTA)7 repeat allele had
higher risk of AIAA, while subjects with at least one
(TTTA)8 repeat allele had lower risk of AIAA (Table 3).
Multivariable analysis
Multivariable models examining the association between
AIAA and TTTA7 and TTTA8 genotypes were adjusted
for time since LMP, reason for menopause, time since
start of AI therapy, education level, and chemotherapy.
Age was not included in the model because of co-linear-
ity with time since LMP. Subjects carrying at least one
7-repeat allele had a non-significant 1.7-fold increase in
odds of AIAA (P = 0.028) after correcting for multiple
testing, while subjects carrying an 8-repeat allele had a
significantly decreased odds of AIAA (OR 0.41 (0.21,
0.79), P = 0.008) (Table 4). In these models, the only
significant clinical predictor of AIAA was time since
menopause, with those who were less than five years
from their LMP at three-fold increased odds of report-
ing AAIA than those who were more than 10 years
from their LMP.
Estrogen levels
Because AIs are known to result in profound estrogen
deprivation, we sought to establish the feasibility of quan-
tifying estrogen levels on women receiving AIs. Of 320
subjects who were currently on AIs and had samples
available for estrogen analyses, estradiol was detectable in
150 subjects (46.9%), while estrone was detectable in
277 subjects (86.6%). The median (range) estradiol and
estrone levels were <1.5 pg/mL (<1.5, 40.3) and 3.3 pg/
mL (<1.7, 60.3), respectively (Figure 1). Estradiol (P =
0.88) and estrone (P = 0.78) levels were no different by
AAIA status.
For subjects who were currently taking AIs, estrone
levels were associated with multiple genotypes. At the
3’UTR locus, carriers of the variant T allele had higher
estrone levels (median (range)) compared to the homozy-
gous wildtype (3.3 pg/mL (<1.7, 69.1) versus 3.1 pg/mL
(<1.7, 32.4), P = 0.03). Variant genotypes at the IVS2







High school or less 29 42.0
College or more 169 52.7
Reasons for menopause 0.13
Natural 98 47.6
Induced 91 55.5
Years since LMP <.001
<5 50 65.8
5 to 10 63 60.6
>10 83 40.7
Body mass index 0.62
<25 97 50.5
25 to 30 68 45.3
>30 68 49.3
Stage 0.991





Chemotherapy, but no Taxane 49 50.2
Chemotherapy included Taxane 90 60.0
Aromatase inhibitors 0.62
Letrozole (Femara) 33 46.5
Anastrozole (Arimidex) 119 49.4
Exemestane (Aromasin) 24 55.8
Years since start of AI1 0.02
<1 56 49.1
1 to 3 67 59.6
>3 55 41.7
Estrogen levels
Detectable estradiol 74 47.4 0.84
Detectable estrone 134 85.9 0.73
Abbreviations: AIAA, Aromatase Inhibitor associated Arthralgia; LMP, last
menstrual period.
1Among those who are currently on AIs.
2Chi-square.
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polymorphism also had significantly higher estrone levels
than the homozygous wildtype genotype (3.3 pg/mL
(<1.7, 69.1) versus 2.0 pg/mL (<1.7, 26.7), P = 0.01). For
the IVS4 polymorphism, the homozygous variant geno-
type (TCT -/-) was associated with higher estrone levels
compared to carriers of the TCT allele (6.3 (<1.7, 18.3)
versus 2.9 (<1.7, 32.4), P = 0.02). Estradiol levels were
not associated with genotypes in this dataset. As
expected, estrogen levels were significantly lower in
women currently on AIs (P < 0.001 for both estradiol
and estrone) than those who discontinued AIs. Further-
more, higher estrogen levels were associated with
shorter time since menopause (P < 0.002 for estrone;
P = 0.01 for estradiol).
Discussion
The introduction of AIs as treatment for hormone
receptor-positive breast cancer has improved disease
free survival for many women; however, arthralgia
related to AIs has caused significant symptom distress
and may contribute to premature discontinuation
among users [16]. We have found that germline poly-
morphic repeats in CYP19A1, the gene encoding aroma-
tase enzyme, are associated with the occurrence of
AIAA. Additionally, the study confirmed our prior find-
ings that shorter time since menopause was a significant
clinical predictor of report of AAIA [3]. These data pro-
vide evidence that the host estrogen environment plays
an important role in the occurrence of AIAA and helps
Table 3 Genotypes and risk of AIAA1
Polymorphism Genotype frequency AIAA
Genotype % (N) % (N) P-value2
C/C 28.1 (107) 50 (54)
3’ UTR C/T (rs10046) C/T 47.8 (182) 54 (98) 0.20
T/T 24.1 (92) 42 (39)
G/G 30.8 (118) 54 (63)
IVS1 A/G (rs749292) G/A 52.2 (200) 48 (96) 0.57
A/A 17.0 (65) 54 (35)
G/G 13.1 (50) 50 (25)
IVS2 G/T (rs727479) G/T 42.7 (163) 52 (84) 0.94
T/T 44.2 (169) 50 (84)
TCT/TCT 44.8 (172) 49 (84)
IVS4 -/TCT (rs11575899) TCT/- 41.4 (159) 51 (81) 0.86
-/- 13.8 (53) 53 (28)
No 7 repeat 28.8 (109) 42 (46) 0.03
Any 7 repeat 71.2 (270) 55 (148)
No 8 repeat 87.1 (330) 53 (176) 0.03
Any 8 repeat 12.9 (49) 37 (18)
(TTTA)n (rs60271534) No 10 repeat 88.7 (336) 51 (173) 0.75
Any 10 repeat 11.3 (43) 49 (21)
No 11 repeat 62.2 (234) 52 (121) 0.92
Any 11 repeat 37.8 (142) 51 (72)
No 12 repeat 88.7 (336) 51 (170) 0.63
Any 12 repeat 11.3 (43) 56 (24)
Abbreviations: AIAA, Aromatase Inhibitor Associated Arthralgia.
1Among Caucasian subjects.
2Chi-square.
Table 4 Multivariable logistic regression analyses: CYP19A variant and AIAA
Risk factors AOR (95% C.I.) P-value AOR (95% C.I.) P-value
Genotype CYP19A 7r CYP19A 8r
Non-carrier (Reference) 1 - 1 -
Carrier 1.70 (1.06 to 2.73) 0.028 0.41 (0.21 to 0.79) 0.008
Time since LMP
>10 years (Reference) 1 - 1 -
5 to 10 years 2.15 (1.27 to 3.67) 0.005 2.14 (1.26 to 3.66) 0.005
<5 years 3.28 (1.71 to 6.29) <0.001 3.31 (1.72 to 6.39) <0.001
Type of menopause
Natural (Reference) 1 - 1 -
Induced 0.82 (0.55 to 1.21) 0.32 0.81 (0.55 to 1.20) 0.30
Years since start of AI
<1 year (Reference) 1 - 1 -
1 to 3 years 1.45 (0.82 to 2.58) 0.20 1.48 (0.83 to 2.62) 0.18
>3 years 0.78 (0.45 to 1.33) 0.36 0.77 (0.45 to 1.33) 0.35
Education
High school 1 - 1 -
College and graduate school 1.02 (0.76 to 1.38) 0.87 1.05 (0.78 to 1.43) 0.93
Chemotherapy
None (Reference) 1 - 1 -
Chemotherapy but no taxane 0.97 (0.54 to 1.74) 0.92 1.02 (0.57 to 1.83) 0.85
Chemotherapy included taxane 1.52 (0.89 to 2.61) 0.12 1.61 (0.93 to 2.78) 0.09
Abbreviations: AOR, adjusted odds ratio; 95% CI, 95% confidence interval; LMP, last menstrual period.
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explain part of the inter-individual variability in symp-
tom experience among patients taking these agents.
The high rate of AIAA in this study confirms previous
reports that AIAA affects almost half of the ambulatory
patients who receive AIs [3,4]. These rates are much
higher than reported in clinical trial settings (18.6% to
35.6%) [17-20] and may be a result of the differences in
patient-reported outcomes versus clinician ascertained
toxicity [21]. Emerging research suggests that patient
reported toxicity more comprehensively capture the sub-
jective side effects of therapies (that is, pain) on daily
experience and have higher concordance with health-
related quality of life than clinician ascertained toxicity;
therefore, it is more appropriate for the investigation of
AIAA [22,23]. Further, only a very small proportion of
all cancer patients participate in clinical trials [24].
Thus, it is possible that selection bias in clinical trial
participants may also lead to decreased incidence of
reported AIAA than the rate in ambulatory settings.
We have identified promising associations between
genetic variation in aromatase and AIAA. Carriers of at
least one 7-repeat allele in the tetranucleotide repeat
polymorphism had non-significant higher risk of AAIA,
while carriers of at least one 8-repeat allele had signifi-
cant lower risk. TTTA7 has been associated with lower
estrogen levels in postmenopausal women and TTTA8
has been associated with higher estrogen levels [14].
These relationships support one possible hypothesis:
women with aromatase enzyme polymorphisms asso-
ciated with lower pre-AI estrogen levels undergo further
estrogen depletion with AI exposure, thereby rendering
them at higher risk of developing AAIA. Other func-
tional polymorphisms and haplotypes in aromatase that
are related to estrogen levels have been described in
resequencing projects [14,25], but we did not find a sig-
nificant association between several of these candidate
polymorphisms and AIAA. An alternative hypothesis
may be that genetic polymorphisms in aromatase gene
may impact the efficacy of aromatase inhibitors and pro-
duce varying degrees of estrogen deprivation. Further
prospective study combining genotyping, high sensitivity
estrogen measurements and AIAA may help test these
hypotheses.
Since AIs are known to cause profound estrogen
deprivation, measuring estrogen levels in AI users is
essential to laying the groundwork for further under-
standing the relationship between these levels and
AIAA. Our assay was highly reliable and extraction
methods minimized measurement of other estrogen
metabolites and drug metabolites of exemestane. How-
ever, we did not find a difference in post-AI estrogen
levels by AIAA status. One explanation may be the
Figure 1 Estrogen levels among subjects currently on aromatase inhibitors.
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already low overall levels of these circulating sex
hormones observed in the study. Although a highly sen-
sitive RIA method was used, a significant proportion of
subjects had estradiol and/or estrone levels below the
level of detection, limiting our discrimination. Presently,
the assay sensitivity for mass spectrometry (MS) for
estradiol is similar to our method (1 to 2 pg/mL). How-
ever, as MS technology advances, it will be possible to
measure extremely low estrogen levels, in the femoto-
gram range, and improve discrimination [26]. Another
explanation is that although we restricted our analysis
to those who self-report current use of AIs, it is possible
that imperfect adherence to AIs may introduce variabil-
ity in estrogen levels and thus confound the analysis
between estrogen levels and AIAA towards null. Finally,
a likely explanation may be that since arthralgia occurs
with the exposure of AIs, it is possible that pre-AI estro-
gen levels or a change in estrogen levels resulting from
AI exposure are more critical to the development of
AIAA. Our findings of an inverse relationship between
time since menopause and estrogen levels and AIAA
risk support this hypothesis.
Although estradiol and estrone levels were not asso-
ciated with AIAA, estrone levels were significantly dif-
ferent among multiple genotypes in the expected
direction. Homozygotes for the t allele at 3’UTR, (TCT)
+ allele at IVS4 and t allele at IVS2 have been observed
to have higher postmenopausal levels of estradiol and
estrone [9]. Estrogen levels were no different among
other genotypes, including TTTAn, a finding that may
also be due to the low circulating hormone levels on
AIs. In these results, we have shown that the relation-
ship between genotype and estrogen levels remained for
some variants even in the setting of AI exposure, and
that estrone rather than estradiol levels were measurably
different. This suggests the utility of estrone as a poten-
tial hormonal biomarker in AI users.
Finally, assessing estradiol and estrone levels in a large
cohort of women exposed to AIs has only been done in
one recent study [27,28]. Using purification steps to
optimize specificity and highly sensitive estradiol and
estrone radioimmunoassays, we demonstrated that a
large proportion of women had both measurable estrone
and estradiol levels. Furthermore, those women who dis-
continued AI therapy had higher estrogen levels than
those who continued. Given the increased concerns
about non-adherence in the setting of adjuvant hormo-
nal treatment [29,30], the appropriate measurement of
these hormones may help determine how post-AI hor-
mones relate to AI-adherence, breast cancer recurrence,
and overall survival in longitudinal studies.
It is important to acknowledge the limitations of the
study. Our outcomes were based on patient-report and
may be subject to recall bias; however, patient-reported
outcomes are considered the gold standard in symptom
and pain research. Further the prevalence and risk of
AIAA in this study were similar to prior samples by our
group and others [3,4], lending credence to this out-
come classification. As with any genetic epidemiology
study, our results are subject to false-positive discovery;
however, our Bonferroni correction strengthens the pos-
sibility that this finding is robust. These results warrant
further confirmatory analysis in larger and independent
cohorts. Third, our cross-sectional study design helps
identify a gene-symptom association that will require
the prospective investigation in the setting of pre and
post AI-exposure and incorporate validated patient-
reported outcomes of joint pain as well as high sensitiv-
ity estrogen analyses to further determine the role of
estrogen deprivation on AIAA. Finally, although our
overall sample had significant proportions of non-
Caucasian subjects, the samples were too small for
meaningful genetic analysis; collaborative studies need
to be established to study how genetic polymorphisms
affect AIAA in minority populations.
Conclusions
This is the largest study to date of patient-reported out-
comes among ambulatory patients taking AIs for adju-
vant breast cancer treatment and the first one to report
genetic determinants of AIAA. These data provide preli-
minary evidence that genes in estrogen synthesis may
modify the risk of AIAA. We also established the feasi-
bility of measuring the estrogen levels of ambulatory AI-
users which allows for future prospective investigation
of the complex relationship among genetic variations,
hormonal changes, and AI related arthralgia and breast
cancer outcomes. It is conceivable that one day, the
combination of genetic and hormonal information may
help clinicians and patients decide how best to use AIs
to maximize benefits, minimize side effects, and opti-
mize both quality of life and survival in women with
breast cancer.
Abbreviations
AI: aromatase inhibitor; AIAA: aromatase inhibitor associated arthralgia; AOR:
adjusted odds ratio; BMI: body mass index; 95% CI: 95% confidence interval;
LMP: last menstrual period; RIA: radioimmunoassay.
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